Lake Mary, Florida (PRWEB) March 09, 2016
Axium Healthcare Pharmacy announced today that it is dispensing Merck’s new fixed dose all-oral ZEPATIER (elbasvir and grazoprevir) for the treatment of chronic hepatitis C (HCV), genotypes 1 and 4, in adults with or without cirrhosis. The medication also received FDA breakthrough therapy designation for use in patients with end-stage renal disease who are on hemodialysis.
ZEPATIER is a single tablet treatment that combines elbasvir, a NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor. The FDA has approved it for treatment with or without ribavirin. In addition, ZEPATIER does not require additional interferon. ZEPATIER is taken once daily, with or without food, and treatment duration ranges from 12 to 16 weeks, depending on HCV genotype.
“Simpler, all-oral dosing, shorter treatment durations, and high success rates represent the continuous advances in today’s HCV therapy options,” commented Mark Montgomery, President and CEO of Axium Healthcare Pharmacy. “These advances are a significant factor in making it easier for patients, and their treating physicians, to manage therapy for the best chances of successful outcomes. Axium is proud to offer patients and physicians today’s most innovative HCV therapy options and support.”
Axium dispenses and supports the ZEPATIER therapy through its HepVisions® program. Full prescribing information for ZEPATIER is available at https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf.
About Axium Healthcare Pharmacy
Founded in 2000, Axium Healthcare Pharmacy, Inc. is a nationwide provider of specialty pharmacy services. A wholly-owned subsidiary of The Kroger Company, Axium provides drug therapies and patient support services to treat chronic, genetic, and other complex conditions such as Hepatitis C, Multiple Sclerosis, Cancer, Rheumatoid Arthritis, and a number of others.
For more information, contact Axium Healthcare Pharmacy at 888.315.3395 or visit http://www.axiumhealthcare.com.